Stay updated on Idasanutlin Combo in AML: Clinical Trial
Sign up to get notified when there's something new on the Idasanutlin Combo in AML: Clinical Trial page.

Latest updates to the Idasanutlin Combo in AML: Clinical Trial page
- Check3 days agoChange DetectedThe Locations section was expanded to include new study sites in New York, Pennsylvania, Texas, Australian Capital Territory, New South Wales, South Australia, Victoria, Ontario, Campania, Emilia-Romagna, Friuli Venezia Giulia, Lazio, Liguria, Lombardy, Piedmont, and Tuscany. Revision: v3.3.3.SummaryDifference1.0%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2. This is a minor, non-functional update that does not alter the study details or how users interact with the page.SummaryDifference0.0%

- Check31 days agoChange DetectedPublications section now states that entries are auto-filled from PubMed. The revision tag has been updated to v3.3.1, replacing the previous v3.2.0 wording.SummaryDifference0.1%

- Check39 days agoChange DetectedThe government funding status notice was removed from the page, while the study details, including the title, eligibility criteria, endpoints, and locations, remain unchanged.SummaryDifference0.2%

- Check53 days agoChange DetectedNo significant changes to core study content were observed; any differences appear limited to minor layout or metadata updates. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check82 days agoChange DetectedThe page now includes an operating-status notice and a version update to v3.2.0, while removing the previous v3.1.0 reference.SummaryDifference1%

Stay in the know with updates to Idasanutlin Combo in AML: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Idasanutlin Combo in AML: Clinical Trial page.